European Commission Approves Novartis’ Cosentyx for PMR
The European Commission approved Novartis’ Cosentyx for polymyalgia rheumatica.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Novartis Receives EU Commission Approval For Cosentyx® In Polymyalgia Rheumatica
Additional Regulatory Reviews Ongoing In US And Japan